Should Aromatase Inhibitor Treatment for Postmenopausal Breast Cancer Be Extended to 10 Years?

Research presented at the American Cancer Society (ASCO) 2016 annual meeting demonstrated that extending use of the aromatase inhibitor drug letrozole from 5 years to 10 years in postmenopausal women with early-stage breast cancer significantly reduced the likelihood of breast cancer recurrence.
Extending the standard 5-year hormone treatment for this patient group to 10 years was observed to reduce breast cancer recurrence risk by 34%.
Women with early-stage hormone receptor-positive breast cancer are known to be at risk of cancer recurrence. This study guides many patients and doctors by confirming that extending aromatase inhibitor treatment duration may reduce breast cancer recurrence risk. It also suggested that longer aromatase inhibitor treatment may have a protective effect against breast cancer.
Hormone receptor-positive breast cancers, by their nature, progress slowly, and cancer recurrence can occur late. Therefore, in most hormonal treatments for breast cancer, the target, compared with overall survival, is instead progression-free survival (the time after treatment until disease worsens or recurs). This study also showed an extension in progression-free survival rather than overall survival.
About the study
The research involved patients previously given, for some time, tamoxifen or one of three aromatase inhibitor treatments as initial treatment for 5 years, in a total of 1918 postmenopausal women. Approximately 90% of patients previously receiving aromatase inhibitor treatment started letrozole or placebo within 6 months after completing their initial treatment.
Patients’ quality of life was measured using a questionnaire including physical and mental health as well as menopause-specific questions. Of the 1918 participants, 1428 were eligible for quality-of-life assessments. These assessments were completed through repeated evaluation at months 12, 24, 36, 48 and 60 in more than 85% of women.
Important findings
Breast cancer recurrence risk decreased by 34% in patients given letrozole during the extended period after initial treatment. The annual incidence of contralateral (opposite breast) breast cancer was lower in the letrozole group (0.21%) than the placebo group (0.49%). Over 5 years, 95% of patients receiving letrozole and 91% of women receiving placebo remained free of breast cancer. Overall survival at 5 years was recorded as 93% in women given placebo and 94% in women given letrozole (this final finding was not statistically significant).
In conclusion, we believe that based solely on this study’s results there are currently insufficient data to recommend extending hormone treatment to 10 years for all patients with early-stage breast cancer. However, extending hormonal treatment for patients with hormone-positive breast cancer who are in a high-risk group despite early-stage disease has become an important development to keep in mind after this study.
Sources
A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.
2016 ASCO Annual Meeting. Abstract No: LBA1
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.